Target intelligence / Profile preview

Cytotoxic DNA crosslinking agent

Molecular classification
Other (not a single molecular entity, but a class of agents), Not a receptor, enzyme, transporter, or protein target
01

Overview

Cytotoxic DNA crosslinking agents are not a single molecular target but rather a class of chemical compounds used primarily as anticancer drugs. They function by forming covalent bonds between two nucleotides on the same or opposite strands of cellular DNA—a process known as DNA crosslinking. This disrupts essential cellular processes including DNA replication and transcription, ultimately triggering cell death through apoptosis. The most clinically relevant forms are alkylating agents (such as nitrogen mustards) and platinum-based compounds like cisplatin. These agents have been foundational components of chemotherapy regimens since their introduction following observations from chemical warfare research during World War II. Their effectiveness is particularly notable against rapidly dividing cancer cells; however, they also damage normal proliferative tissues resulting in significant side effects. The term "cytotoxic DNA crosslinking agent" does not refer to any specific protein target such as an enzyme or receptor but instead describes a pharmacological action shared by several structurally diverse molecules. Therefore it is not considered a canonical therapeutic target itself—it is more accurately described as a drug mechanism category rather than an individual molecular entity suitable for structured database entries about targets. In summary: "Cytotoxic DNA crosslinking agent" refers broadly to any compound capable of inducing lethal covalent linkages within cellular genetic material—a property exploited therapeutically against cancer but associated with substantial risks due its lack of selectivity for malignant over healthy tissue.

Other names
DNA crosslinking agentDNA interstrand crosslinking agentAlkylating agent (when referring to mechanism)Platinum-based chemotherapeutic (for some drugs in this class)
02

Mechanism of action

Drugs in this category act by forming covalent bonds between nucleotides within the same strand or between opposite strands of the DNA double helix. This results in either intra-strand or inter-strand crosslinks that block essential processes like replication and transcription, leading to cell cycle arrest and apoptosis. The most cytotoxic lesions are interstrand crosslinks because they prevent strand separation required for both replication and transcription.

03

Biological functions

Induction of cell deathInhibition of DNA replicationInhibition of transcriptionCell cycle arrest
04

Disease associations

Cancer (primary therapeutic use)Other (potential for research applications in genomic studies)
05

Safety considerations

high toxicity to normal cells—especially rapidly dividing cellsmyelosuppressionnephrotoxicity (notably with cisplatin)neurotoxicitynausea/vomitingsecondary malignancies due to mutagenesisinfertility/sterility risk from gonadal toxicitymucositis/stomatitis
06

Interacting drugs

Cisplatin

5 more in the full profile.

07

Biomarkers

BRCA1 expression level is an important biomarker for sensitivity to platinum-based cytotoxic DNA crosslinkers; low BRCA1 correlates with increased sensitivity due to impaired homologous recombination repair.Mutations or methylation status in BRCA2 and other genes involved in the homologous recombination pathway may also serve as biomarkers.

Beyond the preview

Go deeper on Cytotoxic DNA crosslinking agent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytotoxic DNA crosslinking agent.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call